Richard Kirkner

Rich Kirkner

Contributing Writer

Richard Kirkner is an award-winning journalist and editorial consultant who has specialized in ophthalmology and eye care media for three decades. Based in Philadelphia, his work has been recognized with more than 40 awards for editorial excellence.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

It didn’t take Biogen long to jump back into ophthalmology after announcing its intention in December 2018 to terminate a collaborative agreement with Applied Genetic ...
Read More
Larry Haimovitch, 72, of Mill Valley, California

Larry Haimovitch, 72, Journalist, Advisor and Ophthalmology Leader

Larry Haimovitch, 72, Journalist, Advisor and Ophthalmology Leader Larry Haimovitch, 72, husband of Carie Harris Haimovitch, of Mill Valley, California, died peacefully at home February ...
Read More
10 Takeaways from Roche-Spark Deal

10 Takeaways from Roche’s $4.8 Billion Offer to Acquire Spark Therapeutics

Here are 10 things to know about Roche’s $4.8 billion bid to acquire Spark Therapeutics. Roche’s $114.5-a-share offer is a 122% premium over the closing ...
Read More
How Jim Thimons Helped Bring OIS’ Unique Approach to Talking About Innovation to Optometry and OIS@SECO 2019

How Jim Thimons Helped Bring OIS’ Unique Approach to Talking About Innovation to Optometry and OIS@SECO 2019

When he attended his first Ophthalmology Innovation Summit at the American Society of Cataract and Refractive Surgery a few years ago, Jim Thimons, OD, recalls ...
Read More
Can 2019 Be ‘Transformative’ for AGTC?

After XLRS Gene Therapy Disappoints, AGTC Looks to ‘Transformative Year’

Since announcing disappointing clinical trial results for one of its lead ophthalmic gene therapy candidates and the termination of its collaboration agreement with Biogen, Applied ...
Read More
Can Retina Candidates Find Their Place?

Where Can Emerging Retina Agents Find Their Place in Clinical Practice?

Few therapeutic areas in medicine have a drug pipeline as flush as retina’s, as shown by trial results of a dozen or more emerging therapies ...
Read More
OIS@AAO Has a Record Year; So Does Ophthalmology Sector

OIS@AAO Has a Record Year; So Does Ophthalmology Sector

CHICAGO – A record crowd gathered for the 10th anniversary of OIS@AAO last week in Chicago, and one of the highlights is always the Year ...
Read More
The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The first Ophthalmology Innovation Awards were presented last night at the OIS-X Gala. Here’s a rundown of the award winners. Clinical Innovator: Ike Ahmed, MD ...
Read More
YUTIQ Approval Latest Step in EyePoint’s Transformation

YUTIQ Approval Latest Step in EyePoint’s Transformation

The steroidal implant YUTIQ for treatment of chronic, noninfectious posterior uveitis is the second drug in EyePoint Pharmaceuticals’ ophthalmology portfolio to receive Food and Drug ...
Read More
Preceyes Takes Robotic Surgery Platform, Trial Results to Euretina and AAO

Preceyes Takes Robotic Surgery Platform, Trial Results to Euretina and AAO

Netherlands-based Preceyes BV seems to have taken the lead in the race to develop a robotic platform for retinal surgery as it prepares to demonstrate ...
Read More
First US-Approved Nerve Growth Factor is for the Eye

First US-Approved Nerve Growth Factor is for the Eye

In the use of biological agents for treatment of eye disease, the back of the eye has been pretty much the sole domain thanks to ...
Read More
Novartis’ Plans for Brolucizumab and Beyond

Novartis’ Guerard Shares Plans for Brolucizumab, Lucentis, Gene Therapy, and FocalView App

Coming off the positive feedback at the American Society of Retina Specialists meeting to trial results of the investigative anti-VEGF agent brolucizumab, Frederic Guerard, Novartis’ ...
Read More